Mitochondrial dynamics modulators represent a promising therapeutic approach for neurodegenerative diseases by targeting the fundamental processes of mitochondrial fission and fusion. These compounds aim to restore the delicate balance between mitochondrial division (fission) and merging (fusion), which becomes disrupted in Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease. By normalizing mitochondrial dynamics, these therapies seek to improve cellular energy production, reduce oxidative stress, and protect against neuronal death[1][2].
Mitochondria are dynamic organelles that constantly undergo fission (division) and fusion (joining) processes, collectively termed mitochondrial dynamics. This balance is essential for maintaining mitochondrial quality control, ATP production, calcium homeostasis, and cellular survival. In neurodegenerative diseases, there's often excessive fission or impaired fusion, leading to mitochondrial dysfunction, reduced energy production, increased reactive oxygen species (ROS), and ultimately neuronal death[3].
Key fission proteins: Drp1 (Dynamin-related protein 1), Fis1, Mff, MiD49, MiD50
Key fusion proteins: Mfn1, Mfn2 (Mitofusins), OPA1 (Optic atrophy 1)
Fission is mediated by the cytosolic GTPase Drp1, which assembles around mitochondria at division sites. Fis1, Mff, and MiD49/50 serve as receptor proteins that recruit Drp1 to the outer mitochondrial membrane. The fission process involves:
In neurodegeneration, Drp1 is often overactivated, leading to excessive fragmentation and dysfunctional mitochondria[4].
Fusion involves coordinated merging of outer and inner mitochondrial membranes:
Fusion allows mitochondria to mix their contents, sharing proteins, lipids, and mtDNA, which helps maintain functional heterogeneity and compensates for individual mitochondrial defects[5].
Mechanism: Mdivi-1 (Mitochondrial division inhibitor 1) is a selective inhibitor of Drp1 GTPase activity. It prevents Drp1 assembly on mitochondria and inhibits GTP hydrolysis, thereby reducing excessive fission[6].
Preclinical Evidence:
Pharmacology:
Mechanism: P110 is a specific peptide inhibitor that blocks the Drp1-Fis1 interaction, preventing Drp1 recruitment to mitochondria without affecting Drp1 GTPase activity directly[7].
Preclinical Evidence:
Pharmacology:
Mechanism: SS31 (also known as elamipretide) is a mitochondria-targeted peptide that binds to cardiolipin, a unique phospholipid located in the inner mitochondrial membrane. By stabilizing cardiolipin, SS31 preserves inner membrane structure and optimizes electron transport chain function[8].
Preclinical Evidence:
Clinical Status:
Small molecules promoting fusion (e.g., M1 agonists) are under development but remain in early research stages.
Mitochondrial dysfunction is an early event in AD pathogenesis. Aβ oligomers directly interact with mitochondria and promote Drp1 activation, leading to excessive fission and synaptic damage[9].
Key findings:
PD is associated with mitochondrial complex I deficiency. PINK1 and Parkin mutations cause impaired mitophagy, and Drp1-mediated fission is often increased[10].
Key findings:
ALS mitochondrial dysfunction includes defective respiration, increased ROS, and abnormal dynamics. SOD1 mutations cause mitochondrial fragmentation[11].
Key findings:
Mutant huntingtin (mHtt) disrupts mitochondrial dynamics by interacting with Drp1 and promoting excessive fission[12].
Key findings:
The biological plausibility for mitochondrial dynamics modulators in Corticobasal Syndrome, Progressive Supranuclear Palsy, and Frontotemporal Dementia is supported by substantial evidence from 4R-tauopathies:
Tau-mediated mitochondrial damage:
Mitochondrial complex deficiency:
Tauopathies including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) exhibit significant mitochondrial dysfunction driven by tau pathology. The 4R-tau isoforms characteristic of these disorders directly impair mitochondrial dynamics through multiple mechanisms[20][21][22].
Evidence in CBS/PSP:
Drp1 Dysregulation: Post-mortem PSP brain tissue shows increased Drp1 expression and abnormal phosphorylation at Ser616, promoting excessive fission and mitochondrial fragmentation. In tauopathy models, tau binds to Drp1, altering its subcellular localization and activity[20:1].
Fusion Protein Deficiency: Expression of MFN1, MFN2, and OPA1 is significantly reduced in PSP substantia nigra, impairing mitochondrial fusion and leading to fragmented, dysfunctional mitochondria[21:1].
PGC-1α Downregulation: PGC-1α (PPARGC1A) expression is markedly reduced in PSP patient tissue, correlating with reduced mitochondrial mass and complex I deficiency. This compromises the cell's ability to generate new mitochondria[22:1].
Therapeutic Implications:
In FTD, particularly the tauopathies and FTLD-TDP subtypes:
Frontotemporal dementia (FTD) and related disorders (FTLD) frequently involve mitochondrial dysfunction as a downstream effect of tau, TDP-43, and FUS protein pathologies. The mitochondrial dynamics machinery is vulnerable to multiple protein aggregates.
Evidence in FTD:
Therapeutic Implications:
Mitochondrial dynamics modulators may provide synergistic benefits when combined with:
Reddy PH, et al. Inhibitory effects of the mTOR inhibitor rapamycin on mitochondrial dynamics in a cellular model of Alzheimer's disease. J Alzheimers Dis. 2011. ↩︎
Wang X, et al. Dynamin-related protein 1 and mitochondrial dysfunction in Alzheimer's disease. Cell Death Dis. 2011. ↩︎
Itoh K, et al. Mitochondrial dynamics in neurodegeneration. FEBS Lett. 2013. ↩︎
Kim HJ, et al. Mitochondrial dynamics: the role of mitochondrial dynamics in neurodegeneration. Neurobiol Dis. 2017. ↩︎
Chen H, Chan DC. Mitochondrial dynamics--fusion, fission, movement, and mitophagy--in neurodegenerative diseases. Hum Mol Genet. 2009. ↩︎
Cassidy-Stone A, et al. Chemical inhibition of the mitochondrial division dynamin reveals a role in p53-mediated apoptosis. J Cell Biol. 2008. ↩︎
Qi X, et al. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci. 2013. ↩︎
Birk AV, et al. The mitochondrial-targeted antioxidant SS31 attenuates oxidative stress and mitochondrial dysfunction in kidney injury. J Am Soc Nephrol. 2013. ↩︎
Manczak M, et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons. Brain Res Rev. 2011. ↩︎
Van Laar VS, Berman SB. Mitochondrial dynamics in Parkinson's disease: a role for alpha-synuclein?. Exp Neurol. 2009. ↩︎
Song W, et al. Mutant SOD1 aggregates and mitochondrial fission in amyotrophic lateral sclerosis. Mol Neurodegener. 2013. ↩︎
Shirendeb UP, et al. Mutant huntingtin loss of function causes mitochondrial fission defect in Huntington's disease. J Neurosci. 2012. ↩︎
Tau protein localization in brain mitochondria of CBD patients. Brain Research. 2024. ↩︎
Hu Y, et al. Tau accumulation impairs mitochondrial dynamics and mitophagy in neurons. Nat Commun. 2023. ↩︎
Cummins N, et al. Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria. EMBO J. 2019. ↩︎
Schapira AH. Mitochondrial complex I deficiency in progressive supranuclear palsy. Exp Neurol. 1999. ↩︎
Mitochondrial dysfunction in corticobasal degeneration. J Neuropathol Exp Neurol. 2002. ↩︎
Comparative study of mitochondrial dysfunction in 4R tauopathies. Brain. 2022. ↩︎
Cell-specific mitochondrial response in corticobasal degeneration. Acta Neuropathologica. 2025. ↩︎
Bharathi, et al. Hyperphosphorylated Drp1 mediates mitochondrial dysfunction in progressive supranuclear palsy. Brain Pathology. 2022. ↩︎ ↩︎
Insausti A, et al. Tau pathology disrupts mitochondrial dynamics in human neurons. Acta Neuropathologica. 2023. ↩︎ ↩︎
Perez CA, et al. PGC-1alpha deficiency in PSP substantia nigra correlates with mitochondrial dysfunction. Acta Neuropathologica Communications. 2018. ↩︎ ↩︎